| Table 3 presents the adverse drug reactions (ADRs) reported during clinical studies in which 6,755 patients received Ferinject, as well as those reported from the post-marketing experience (see table footnotes for details).The most commonly reported ADR is nausea (occurring in 3.1% of the patients), followed by headache, dizziness, and hypertension. Injection site reactions categorised as common in Table 3 are comprised of several ADRs which individually have been reported with a frequency of either uncommon or rare. Hypophosphataemia (common) may occur. In clinical trials the minimum values were obtained after approximately 2 weeks, and 4 to 12 weeks following Ferinject treatment the values had returned to those within the range of baseline. The most serious ADR is anaphylactoid reactions with a frequency of rare. Table 3: Adverse drug reactions observed during clinical trials and post-marketing experienceSystem Organ Class | Common (≥1/100 to <1/10) | Uncommon (≥1/1000 to <1/100) | Rare (≥1/10000 to <1/1000) | Immune system disorders | | Hypersensitivity
| Anaphylactoid reactions
| Nervous system disorders | Headache, dizziness
| Paraesthesia,
dysgeusia
| Loss of consciousness(3) | Psychiatric disorders | | | Anxiety(4) | Cardiac disorders | | Tachycardia
| | Vascular disorders | Hypertension
| Hypotension, flushing
| Phlebitis,
syncope(4), presyncope(4) | Respiratory, thoracic and mediastinal disorders | | Dyspnoea
| Bronchospasm(4) | Gastrointestinal disorders | Nausea
| Vomiting, dyspepsia, abdominal pain, constipation, diahorrea
| Flatulence
| Skin and subcutaneous tissue disorders | | Pruritus, urticaria, erythema, rash(1) | Angioedema(4), pallor(3), and face oedema(3) | Musculoskeletal and connective tissue disorders | | Myalgia, back pain, arthralgia, muscle spasms
| | General disorders and administration site conditions | Injection site
reactions(2) | Pyrexia, fatigue, chest pain, oedema peripheral, chills
| Rigors, malaise
| Investigations | Alanine aminotransferase increased
| Aspartate aminotransferase increased, gamma-glutamyltransferase increased, blood lactate dehydrogenase increased, blood alkaline phosphatase increased
| | Metabolism and nutritional disorders | Hypophosphataemia
| | | 1 Includes the following preferred terms: rash (individual ADR frequency determined as uncommon) and rash erythematous, -generalised, -macular, -maculo-papular, -pruritic (all individual ADRs are frequency determined as rare).2 Includes the following preferred terms: infusion site burning, -pain, -bruising, -discolouration, -extravasation, -irritation, reaction, (all individual ADRs are frequency determined as uncommon) and -paraesthesia (individual ADR frequency determined as rare).3 ADRs exclusively reported in the post-marketing setting.4 ADRs reported in the post-marketing setting which were also observed in the clinical setting.Note: ADR = Adverse drug reaction.Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:United Kingdom Yellow Card SchemeWebsite: www.mhra.gov.uk/yellowcardMalta ADR ReportingThe Medicines Authority Post-Licensing Directorate203 Level 3, Rue D'ArgensGŻR-1368 GżiraWebsite: www.medicinesauthority.gov.mte-mail: postlicensing.medicinesauthority@gov.mt | |